Clinical trial • Not applicable • Endocrinology
SODIUM LACTATE for Diabetic ketoacidosis
Not applicable trial of SODIUM LACTATE for Diabetic ketoacidosis.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Diabetic ketoacidosis
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 27-09-2024
- First CTIS Authorization Date
- 10-01-2025
Trial design
Randomised, isotonic saline (sodium chloride infusion) versus ringer lactate (sodium lactate infusion); dose and schedule not specified in the available documentation.-controlled Not applicable trial across 16 sites in France.
- Randomised
- Yes
- Comparator
- Isotonic saline (SODIUM CHLORIDE infusion) versus Ringer lactate (SODIUM LACTATE infusion); dose and schedule not specified in the available documentation.
- Target Sample Size
- 300
- Trial Duration For Participant
- 1
Eligibility
Recruits 300 isVulnerablePopulationSelected: true. Informed consent obtained from adult participants using subject information and informed consent forms (documents: L1_SIS and ICF_adults). Specific forms are available for third parties/legal representatives (L1_SIS and ICF_Tiers), emergency situations (L2_Other subject information_Situation Urgence), and post-death/third-party post information (L1_SIS_TIERS-suite deces patient_FP, L1_SIS and ICF_TIERS-POST_FP). Minors are excluded (Patients <18 ans) so assent for children is not applicable..
- Pregnancy Exclusion
- Pregnant women
- Vulnerable Population
- isVulnerablePopulationSelected: true. Informed consent obtained from adult participants using subject information and informed consent forms (documents: L1_SIS and ICF_adults). Specific forms are available for third parties/legal representatives (L1_SIS and ICF_Tiers), emergency situations (L2_Other subject information_Situation Urgence), and post-death/third-party post information (L1_SIS_TIERS-suite deces patient_FP, L1_SIS and ICF_TIERS-POST_FP). Minors are excluded (Patients <18 ans) so assent for children is not applicable.
Inclusion criteria
- {"criterion_text":"- Admission to emergency department or direct admission to ICU"}
- {"criterion_text":"- Diagnosis of severe diabetic ketoacidosis requiring all the following criteria: o Blood or capillary glucose > 11 mmol/L o Ketonemia or ketonuria > 0 o Venous or arterial pH < 7.30 or venous or arterial bicarbonate < 15 mmol/L"}
- {"criterion_text":"- Volume of fluid administered before inclusion <1L"}
Exclusion criteria
- {"criterion_text":"- Patients <18 ans"}
- {"criterion_text":"- Pregnant women"}
- {"criterion_text":"- Contraindication to isotonic saline or Ringer Lactate"}
- {"criterion_text":"- Patients with a decision to withdraw life-sustaining therapy"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission : 1. capillary or blood glucose < 11 mmol/L 2. undetectable ketonemia or ketonuria 3. venous or arterial pH > 7.35 or venous or arterial bicarbonate > 20 mmol/L","definition_or_measurement_approach":"Proportion of patients meeting all three biochemical criteria measured at 24 hours from ICU admission (capillary/blood glucose, ketonemia/ketonuria, venous/arterial pH or bicarbonate)."}
Recruitment
- Planned Sample Size
- 300
- Recruitment Window Months
- 25
- Consent Approach
- Informed consent obtained from adult participants. Subject information and informed consent forms available for adults (L1_SIS and ICF_adults). Specific documents are provided for third-party/legal representatives (L1_SIS and ICF_Tiers), emergency inclusion situations (L2_Other subject information_Situation Urgence), and post-event/third-party post information (L1_SIS and ICF_Patient-Post, L1_SIS_TIERS-suite deces patient_FP, L1_SIS and ICF_TIERS-POST_FP). Documents appear to be in French (trial conducted in France). Minors are excluded from the trial.
Geography
- Total Number Of Sites
- 16
- Total Number Of Participants
- 300
France
- Earliest CTIS Part Ii Submission Date
- 05-11-2024
- Latest Decision Or Authorization Date
- 12-02-2026
- Processing Time Days
- 464
- Number Of Sites
- 16
- Number Of Participants
- 300
Sites
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Service Médecine Intensive Réanimation
- Contact Person Name
- HAFID AIT-OUFELLA
- Contact Person Email
- hafid.aitoufella@aphp.fr
- Site Name
- Les Hopitaux Universitaires De Strasbourg
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Julien DEMISELLE
- Contact Person Email
- julien.demiselle@chru-strasbourg.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Jean REIGNIER
- Contact Person Email
- jean.reignier@chu-nantes.fr
- Site Name
- Centre Hospitalier D Avignon
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Gael PRADEL
- Contact Person Email
- pradel.gael@ch-avignon.fr
- Site Name
- Centre Hospitalier Et Universitaire De Limoges
- Department Name
- Service des Urgences
- Contact Person Name
- Aloïse BLANCHET
- Contact Person Email
- Aloise.BLANCHET@chu-limoges.fr
- Site Name
- Centre Hospitalier D'Antibes Juan Les Pins
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Cécilia BENARD
- Contact Person Email
- cecilia.benard@ch-antibes.fr
- Site Name
- Centre Jean Perrin
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Bertrand SOUWEINE
- Contact Person Email
- bsouweine@chu-clermontferrand.fr
- Site Name
- Centre Hospitalier Universitaire De Montpellier
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Boris JUNG
- Contact Person Email
- b-jung@chu-montpellier.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Louis CHAUVELOT
- Contact Person Email
- louis.chauvelot@chu-lyon.fr
- Site Name
- Centre Hospitalier Universitaire De Nice
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- MATHIEU JOZWIAK
- Contact Person Email
- jozwiak.m@chu-nice.fr
- Site Name
- Centre Hospitalier Universitaire De Nimes
- Department Name
- Service Médecine Intensive Réanimation
- Contact Person Name
- CLAIRE ROGER
- Contact Person Email
- claire.roger@chu-nimes.fr
- Site Name
- Centre Hospitalier Intercommunal De Frejus-Saint-Raphaeel
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Anthony VEYRON
- Contact Person Email
- anthony.veyron@chi-fsr.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Sébastien PREAU
- Contact Person Email
- sebastien.preau@chru-lille.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Xavier MONNET
- Contact Person Email
- xavier.monnet@aphp.fr
- Site Name
- Centre Hospitalier Regional De Marseille
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Sami HRAIECH
- Contact Person Email
- sami.hraiech@ap-hm.fr
- Site Name
- Centre Hospitalier De Cannes Simone Veil
- Department Name
- Service de Médecine Intensive Réanimation
- Contact Person Name
- Pierre-Marie BERTRAND
- Contact Person Email
- pm.bertrand@ch-cannes.fr
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire De Nice
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- SODIUM LACTATE
- Active Substance
- SODIUM LACTATE
- Modality
- Small molecule
- Routes Of Administration
- INFUSION
- Route
- INFUSION
- Maximum Dose
- 7 l
- Investigational Product Name
- SODIUM CHLORIDE
- Active Substance
- SODIUM CHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INFUSION
- Route
- INFUSION
- Maximum Dose
- 7 l
Related trials
Other published trials that may interest you.